Table 2.
Baseline characteristics for patients, stratified by presence of diabetes*
| No diabetes n=473 | Diabetes N=31 | P value | |||
| Demographic | |||||
| Age, mean (SD) | 54.2 | (13.8) | 57.1 | (12.2) | 0.26 |
| Sex female, % | 31 | 52 | 0.03 | ||
| Smoking, % | 35 | 48 | 0.12 | ||
| Body mass index, mean (SD) | 25.9 | (4.2) | 27.1 | (3.5) | 0.13 |
| Randomisation arm | 0.68 | ||||
| Sequential monotherapy | 118 | (25) | 8 | (26) | |
| Step-up combination therapy | 110 | (23) | 10 | (32) | |
| Initial combination with prednisone | 124 | (26) | 6 | (19) | |
| Initial combination with infliximab | 121 | (26) | 7 | (23) | |
| Disease related | |||||
| Symptom duration (days), median (IQR) | 23.7 | (13.9–54.2) | 19.6 | (12.0–32.6) | 0.08 |
| RF-positive, % | 65 | 68 | 0.85 | ||
| ACPA-positive, % | 62 | 62 | 1.00 | ||
| DAS, mean (SD) | 4.4 | (0.9) | 4.4 | (0.8) | 0.81 |
| HAQ, mean (SD) | 1.4 | (1.0–1.9) | 1.3 | (0.9–1.9) | 0.99 |
| SHS, median (IQR) | 1.5 | (0–5.5) | 2 | (0–5) | 0.85 |
*Comparisons were tested with t-tests, Mann-Whitney U tests or Fisher’s exact tests, as appropriate.
ACPA, anticitrullinated peptide antibody; DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHS, total Sharp/vanderHeijde Score.